NCT04566666

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 263 (actual)
• Sponsor: Sun Pharmaceutical Industries Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

Detailed description

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to determine the effect of SCD-044 in subjects with moderate to severe plaque psoriasis.

Conditions

• Moderate to Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Placebo	Placebo of SCD-044 product
DRUG	SCD-044_Low Dose (Dose 1)	SCD-044 tablets in Low Dose (Dose 1)
DRUG	SCD-044_Intermediate Dose (Dose 2)	SCD-044 tablets in Intermediate Dose (Dose 2)
DRUG	SCD-044_High Dose (Dose 3)	SCD-044 in High Dose (Dose 3)

Timeline

• Start date: 2021-03-25
• Primary completion: 2024-11-20
• Completion: 2025-08-27
• First posted: 2020-09-28
• Last updated: 2026-01-20
• Results posted: 2026-01-20

Locations

50 sites across 5 countries: United States, El Salvador, Estonia, Georgia, Poland

Regulatory

• FDA-regulated drug study